FDA STeP Eligibility Calculator

This tool gives a structured first-pass estimate of whether your device narrative likely aligns with the FDA Safer Technologies Program (STeP). It does not replace direct FDA interaction or legal judgment, but it helps teams eliminate weak assumptions before they commit to a full submission strategy.

Calculator Inputs

Condition seriousness level

Expected safety improvement

Current evidence maturity

Likely downstream pathway clarity

Risk management plan quality

Q-Sub readiness

Run the calculator to generate your preliminary STeP fit score and action checklist.

Plan next steps with provider benchmarks

After scoring, compare execution models in our directory.

Compare +50 FDA STeP providers

How This Calculator Reflects Real Search Intent

Teams usually search for STeP support when they are not looking for basic definitions anymore. They are trying to make a decision under uncertainty: whether STeP is worth the process overhead now, whether to allocate scarce test budget before a Q-Sub discussion, and whether external providers are required to move quickly. That intent shows up in high-conversion keyword patterns like “FDA STeP eligibility calculator,” “STeP criteria medical device,” “STeP vs Breakthrough device,” “how to qualify for STeP,” and “Safer Technologies Program submission strategy.”

This page was designed against that practical intent. Instead of a generic checklist, the model quantifies six decision vectors that repeatedly drive regulatory outcomes: condition seriousness framing, safety improvement measurability, objective evidence readiness, pathway clarity, risk control quality, and FDA interaction readiness. In other words, the page is structured to answer the exact question users ask after clicking these terms: “Do we likely fit, and what should we fix first if we do not?”

Keyword relevance without utility creates thin content. Utility without intent matching creates low visibility. The best SEO pages combine both. That is why every section below links the score to next actions and specific FDA references, so a user can move from awareness to execution in one session instead of bouncing between disconnected articles.

What STeP Is and Is Not

The FDA Safer Technologies Program is not a shortcut that waives quality standards. It is a framework intended to facilitate more efficient development and review interactions for devices expected to significantly improve safety relative to available treatment or diagnostics for diseases or conditions that are less serious than those in the Breakthrough program scope. This distinction matters. Many teams misclassify their product by focusing on novelty while ignoring condition framing, comparator definition, and measurable safety endpoints.

STeP is strongest when your team can show a credible chain from problem context to safety delta to verification evidence. For example, reducing a known procedural hazard through redesigned controls may be persuasive if you can quantify the change in use error probability, misuse severity, or adverse event likelihood under realistic use conditions. By contrast, broad statements like “improves workflow safety” without a robust measurement strategy usually fail to carry review weight.

Another common confusion point is overlap with Breakthrough Devices. If your disease or condition may be considered life-threatening or irreversibly debilitating, the Breakthrough pathway may be more appropriate. Teams should not force STeP fit just because they perceive lower friction. The program choice needs to align with both condition context and benefit claims, or the same content must later be reframed during regulatory interactions, causing avoidable delays.

Interpreting Your Score

80-100 (High preliminary fit): Your narrative likely has reasonable STeP alignment. Prioritize Q-Sub objective clarity, endpoint defensibility, and consistency across intended use, labeling claims, and risk controls. High scores still require careful drafting and traceable evidence management.

55-79 (Moderate fit): You may have a plausible STeP direction, but one or more structural gaps could weaken your rationale. Typical fixes include tightening comparator definitions, expanding usability or bench validation, or improving risk-traceability links between hazards, controls, and tests.

Below 55 (Low fit): You likely need to revisit framing fundamentals before investing in detailed STeP positioning. Reassess condition classification, expected safety improvement claims, and pathway hypotheses. In many cases, teams in this range save time by conducting a focused strategy sprint before drafting outward-facing documents.

These ranges are intentionally conservative. The calculator is designed to avoid false confidence because optimistic internal assumptions are one of the biggest drivers of submission churn. Use the result as a prioritization tool, not as a final regulatory decision.

Evidence Architecture That Improves STeP Conversations

Strong teams build an evidence architecture before they build presentation slides. That means each claim should map to specific data assets, each data asset should map to a method, and each method should map to an acceptance criterion tied to user safety. If this structure is missing, reviewers must infer your logic, and inferred logic is fragile. The calculator rewards explicit structure for this reason.

A practical architecture often includes: a claim inventory, risk control matrix, usability/human factors protocol alignment, software and cybersecurity rationale where applicable, and a consolidated decision log explaining why each endpoint supports the safety-improvement thesis. When these pieces are present, Q-Sub questions become sharper, provider collaboration becomes faster, and downstream 510(k) or De Novo modules can reuse content with fewer contradictions.

Teams often underestimate the value of version control and rationale capture. During iterative feedback cycles, evidence does not just grow; it changes shape. Without explicit rationale tracking, your intended-use language, endpoint logic, and risk assumptions drift apart. The result is rework that can consume weeks. Mature evidence governance is therefore not administrative overhead. It is timeline protection.

Operational Mistakes This Page Helps You Avoid

Overstating improvement: Claiming broad safety advantages without specifying measurable comparator outcomes.
Under-scoping evidence: Entering interactions with concept narratives but no objective acceptance criteria.
Pathway drift: Treating STeP as isolated from future 510(k)/De Novo content requirements.
Late risk integration: Drafting strategy documents before risk controls are mapped to test evidence.
Weak provider briefs: Contacting vendors without quantified scope, producing generic proposals and inflated timelines.

Each of these mistakes is common because teams are usually moving fast across R&D, quality, regulatory, and commercial constraints. Structured tools do not eliminate complexity, but they convert ambiguity into sequenced decisions. That is the core purpose of this calculator and the associated pages in this cluster.

Internal Linking Path for Teams Executing This Week

If your score indicates moderate or high preliminary fit, continue with the STeP engagement timeline calculator and then the resource and budget calculator. If your score is low, revisit your submission fundamentals through the 510(k) checklist, predicate analysis guide, and eSTAR workflow guide before scheduling external support discussions.

For provider selection, use the structured comparison in Compare +50 FDA STeP providers. Present your score output and ask each candidate provider to challenge it with explicit assumptions. This is the fastest way to distinguish strategic partners from generic writing vendors.

FAQ

Does a high score mean FDA will accept STeP designation?

No. A high score means your current narrative and evidence maturity appear directionally aligned. FDA interaction and case-specific context remain decisive.

Can software-only devices use this model?

Yes, but only if safety-improvement claims are measurable and supported by a robust risk and verification architecture. Software novelty alone is insufficient.

How often should we rerun the score?

Rerun after major evidence updates, indication changes, or pathway changes. Most teams benefit from rerunning at each decision gate.